These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 19012056)
1. Invasive, paediatric, vaccine strains of Streptococcus pneumoniae: are there differences in clinical characteristics? Trollfors B; Berg S; Backhaus E; Andersson R; Bossen Konradsen H Scand J Infect Dis; 2009; 41(2):84-7. PubMed ID: 19012056 [TBL] [Abstract][Full Text] [Related]
2. Streptococcus pneumoniae serogroups 15 and 33: an increasing cause of pneumococcal infections in children in the United States after the introduction of the pneumococcal 7-valent conjugate vaccine. Gonzalez BE; Hulten KG; Lamberth L; Kaplan SL; Mason EO; Pediatr Infect Dis J; 2006 Apr; 25(4):301-5. PubMed ID: 16567980 [TBL] [Abstract][Full Text] [Related]
3. Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae? Fenoll A; Aguilar L; Granizo JJ; Giménez MJ; Aragoneses-Fenoll L; Mendez C; Tarragó D J Antimicrob Chemother; 2008 Dec; 62(6):1430-3. PubMed ID: 18819966 [TBL] [Abstract][Full Text] [Related]
4. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Hausdorff WP; Bryant J; Paradiso PR; Siber GR Clin Infect Dis; 2000 Jan; 30(1):100-21. PubMed ID: 10619740 [TBL] [Abstract][Full Text] [Related]
6. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Hausdorff WP; Bryant J; Kloek C; Paradiso PR; Siber GR Clin Infect Dis; 2000 Jan; 30(1):122-40. PubMed ID: 10619741 [TBL] [Abstract][Full Text] [Related]
7. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Aguiar SI; Serrano I; Pinto FR; Melo-Cristino J; Ramirez M; Clin Microbiol Infect; 2008 Sep; 14(9):835-43. PubMed ID: 18844684 [TBL] [Abstract][Full Text] [Related]
8. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)]. Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998 [TBL] [Abstract][Full Text] [Related]
9. The shifting dynamics of pneumococcal invasive disease after the introduction of the pneumococcal 7-valent conjugated vaccine: toward the new pneumococcal conjugated vaccines. Greenberg D Clin Infect Dis; 2009 Jul; 49(2):213-5. PubMed ID: 19508164 [No Abstract] [Full Text] [Related]
10. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Kellner JD; Vanderkooi OG; MacDonald J; Church DL; Tyrrell GJ; Scheifele DW Clin Infect Dis; 2009 Jul; 49(2):205-12. PubMed ID: 19508165 [TBL] [Abstract][Full Text] [Related]
11. Historical changes in pneumococcal serogroup distribution: implications for the era of pneumococcal conjugate vaccines. Feikin DR; Klugman KP Clin Infect Dis; 2002 Sep; 35(5):547-55. PubMed ID: 12173128 [TBL] [Abstract][Full Text] [Related]
12. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Jacobs MR; Good CE; Bajaksouzian S; Windau AR Clin Infect Dis; 2008 Dec; 47(11):1388-95. PubMed ID: 18959493 [TBL] [Abstract][Full Text] [Related]
13. Serotypes of Streptococcus pneumoniae isolated from blood and cerebrospinal fluid related to vaccine serotypes and to clinical characteristics. Berg S; Trollfors B; Persson E; Backhaus E; Larsson P; Ek E; Claesson BE; Jonsson L; Rådberg G; Johansson S; Ripa T; Kaltoft MS; Konradsen HB Scand J Infect Dis; 2006; 38(6-7):427-32. PubMed ID: 16798688 [TBL] [Abstract][Full Text] [Related]
14. Re: Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Prymula R Vaccine; 2009 Jul; 27(35):4739-40. PubMed ID: 19540951 [TBL] [Abstract][Full Text] [Related]
15. Serotype distribution and antimicrobial resistance of invasive and non-invasive pneumococccal isolates in Asturias, Spain. García-Suárez Mdel M; Villaverde R; Caldevilla AF; Méndez FJ; Vázquez F Jpn J Infect Dis; 2006 Oct; 59(5):299-05. PubMed ID: 17060695 [TBL] [Abstract][Full Text] [Related]
16. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae. Dagan R Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():16-20. PubMed ID: 19366365 [TBL] [Abstract][Full Text] [Related]
17. Invasive pneumococcal disease in children aged <5 years admitted to 3 urban hospitals in Ibadan, Nigeria. Falade AG; Lagunju IA; Bakare RA; Odekanmi AA; Adegbola RA Clin Infect Dis; 2009 Mar; 48 Suppl 2():S190-6. PubMed ID: 19191615 [TBL] [Abstract][Full Text] [Related]
18. Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines. Picazo JJ Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():4-6. PubMed ID: 19366362 [TBL] [Abstract][Full Text] [Related]
19. Cross-sectional study of nasopharyngeal carriage of Streptococcus pneumoniae in human immunodeficiency virus-infected adults in the conjugate vaccine era. Onwubiko C; Swiatlo E; McDaniel LS J Clin Microbiol; 2008 Nov; 46(11):3621-5. PubMed ID: 18845823 [TBL] [Abstract][Full Text] [Related]
20. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]